Effects of long-term cysteamine treatment in patients with cystinosis by Ariceta, Gema et al.
REVIEW
Effects of long-term cysteamine treatment in patients with cystinosis
Gema Ariceta1,2 & Vincenzo Giordano3 & Fernando Santos4
Received: 3 September 2017 /Revised: 5 November 2017 /Accepted: 16 November 2017 /Published online: 19 December 2017
# The Author(s) 2017. This article is an open access publication
Abstract
Cystinosis is a rare autosomal-recessive lysosomal storage disease with high morbidity and mortality. It is caused bymutations in
the CTNS gene that encodes the cystine transporter, cystinosin, which leads to lysosomal cystine accumulation. Patients with
infantile nephropathic cystinosis, the most common and most severe clinical form of cystinosis, commonly present with renal
Fanconi syndrome by 6–12 months of age, and without specific treatment, almost all will develop end-stage renal disease
(ESRD) by 10–12 years of age. Early corneal cystine crystal deposition is a hallmark of the disease. Cystinosis also presents
with gastrointestinal symptoms (e.g., vomiting, decreased appetite, and feeding difficulties) and severe growth retardation and
may affect several other organs over time, including the eye, thyroid gland, gonads, pancreas, muscles, bone marrow, liver,
nervous system, lungs, and bones. Cystine-depleting therapy with cysteamine orally is the only specific targeted therapy available
for managing cystinosis and needs to be combined with cysteamine eye drops for corneal disease involvement. In patients with
early treatment initiation and good compliance to therapy, long-term cysteamine treatment delays progression to ESRD, signif-
icantly improves growth, decreases the frequency and severity of extrarenal complications, and is associated with extended life
expectancy. Therefore, early diagnosis of cystinosis and adequate life-long treatment with cysteamine are essential for preventing
end-organ damage and improving the overall prognosis in these patients.
Keywords CTNS gene mutations . Cystine-depleting therapy . End-stage renal disease . Extrarenal complications . Lysosomal
cystine accumulation . Renal Fanconi syndrome
Introduction
Cystinosis is a rare autosomal-recessive lysosomal storage
disease occurring approximately once every 100,000–
200,000 live births, that is associated with high morbidity
and mortality [1, 2]. The disease is caused by mutations in
the CTNS gene that encodes the lysosomal cystine transporter,
cystinosin, which result in the accumulation of cystine within
the lysosome [3, 4]. There are three clinical forms of
cystinosis: infantile or early-onset nephropathic cystinosis
(OMIM 219800), juvenile or late-onset nephropathic
cystinosis (OMIM 219900), and adult or ocular cystinosis
(OMIM 219750) [1, 2]. Infantile nephropathic cystinosis is
the most severe and most common form (~95% of cases)
and that in which apparently healthy neonates usually present
with renal Fanconi syndromewithin the first year of life. In the
absence of appropriate treatment, these patients develop end-
stage renal disease (ESRD) by 10–12 years of age [5, 6]. The
availability of renal replacement therapy (RRT) (i.e., dialysis
and renal transplantation) since the early 1980s has improved
the prognosis of patients with nephropathic cystinosis [7], but
longer patient survival has highlighted the emergence of late
manifestations of the disease. These extrarenal complications
may develop in several organs, including the eye, thyroid
gland, pancreas, gonads, lungs, muscles, brain, and bones
[8–13]. Early diagnosis and adequate treatment is essential
to prevent or attenuate end-organ damage and improve overall
prognosis [14].
Life-long cystine-depleting therapy with cysteamine orally
is the mainstay of treatment for cystinosis, and if initiated
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early, it can dramatically improve renal survival, patient’s
quality of life, and overall disease prognosis [1, 15]. The most
commonly used formulation is immediate-release cysteamine
bitartrate (Cystagon®, Mylan Pharma, USA, and Orphan
Europe, France), which has been on the market since the
1990s, and delayed-release cysteamine bitartrate (Procysbi®,
Horizon Pharma, USA) was recently approved. Early and
continuous long-term treatment with cysteamine is associated
with delayed ESRD onset, a decreased risk of extrarenal com-
plications, and improved survival rates [16, 17]. Frequency
and severity of complications are decreased in patients with
good compliance to cysteamine therapy [18, 19]. However,
adolescents and adults tend to show lower treatment adher-
ence after transition from pediatric to adult medical care.
Given that the life expectancy of patients with cystinosis has
now been increased into adulthood, as yet uncharacterized
complications may emerge in well-treated adult patients with
cystinosis [17].
Here we provide a brief overview of the pathogenesis of
cystinosis and describe the long-term benefits of sustained
cysteamine therapy, including reduced renal and extrarenal
complications and increased life expectancy in patients with
cystinosis.
Pathogenesis of cystinosis
Cystinosis is caused by bi-allelic mutations in the CTNS gene
located on chromosome 17p13.2 that encodes for cystinosin, a
ubiquitously expressed membrane protein that mediates the
efflux of lysosomal cystine [3, 4, 20]. The most common
CTNS mutation in Western populations is a large ~57-kb de-
letion that includes the D17S829 locus [3, 4], as well as the
CARKL gene that encodes the enzyme sedoheptulokinase
[21]. Nephropathic cystinosis is usually associated with two
severe or truncating CTNS mutations that affect the promoter,
leader sequence, transmembrane or non-transmembrane re-
gions, including small deletions/insertions, missense and
splicing mutations [1].
Although the exact mechanism of cystinosis is not fully
understood, the lack of functional cystinosin is known to
cause accumulation and crystallization of cystine within the
lysosome, which ultimately results in apoptosis and tissue
damage in all organ systems [22, 23]. Lysosomal cystine crys-
tals are thought to cause elevated intracellular oxidative stress
[24] and may activate inflammasome-related gene expression
in proximal tubular epithelial cells [25]. In addition to cystine
accumulation, studies have indicated that changes in the ex-
pression of transcription factors [26] and the mammalian tar-
get of rapamycin signaling pathway [27] may also play a role
in the pathogenesis of cystinosis. Other mechanisms, such as
the expression of abnormal cystinosin protein itself, increased
apoptosis, proximal tubular cell metaplasia, and damage to
podocytes, are also likely to play a role in the associated renal
impairment[23, 28].
Cysteamine therapy
Cysteamine enters the lysosome by an unknown transporter
and breaks down cystine into cysteine and cysteine–cyste-
amine disulfide, which are removed by the cysteine transport-
er and the lysine/arginine (PQLC2) transporter, respectively
(Fig. 1) [29, 30]. Cysteamine rapidly deplete cells and tissues
of lysosomal cystine [31] and is the only specific targeted
therapy available for patients with cystinosis [1]. Based on
the efficacy of orally administered cysteamine in slowing re-
nal function decline [6, 32], the drug was approved for clinical
use in the 1990s.
In vitro, cysteamine is associated with restoration of gluta-
thione redox status in cultured cystinotic renal tubular epithe-
lial cells [33] and differentiation of mesenchymal stromal
bone marrow cells [34]. Cysteamine also increases spermato-
genesis [35], reduces oxidative stress [36, 37], and prevents
inhibition of thiol-containing enzymes [38–40].
Cysteamine dosage calculations are based on body surface
area (BSA) in adults, with a maximum dose of 1.95 g/m2 per
day [17]. Intracellular leukocyte cystine (ILC) levels, which
are typically >2 nmol half-cystine/mg protein in patients with
cystinosis [1], may be monitored to optimize cysteamine dose
and help identify patients with poor compliance. Target ILC
trough levels of <1 nmol half-cystine/mg protein are used for
adequate disease control and cysteamine dose adjustment [6].
However, it should be noted that ILC levels can vary between
laboratories, and the exact benefits of measuring levels is not
well established.
At higher doses (>1.95 g/m2 per day) of cysteamine, rare
adverse effects have been reported, including bone pain, my-
algia, skin striae, and bruise-like lesions on the elbows (reac-
tive angioendotheliomatosis on skin biopsy) [41]. Cysteamine
increases human dermal microvascular endothelial cell sur-
vival in vitro, which may explain how the drug causes
angioendotheliomatosis [42]. As it is metabolized into volatile
sulfur compounds (i.e., dimethyl sulfide and methanethiol),
treatment is also associated with an unpleasant sulfurous body
and breath odor, which can often lead to poor treatment com-
pliance [41].
Other cysteamine-related adverse events include allergic
rash, hyperthermia, lethargy, neutropenia, seizures, and gas-
trointestinal discomfort; however, these effects are reversible,
and most are prevented by starting the drug at a low dosage
with gradual titration as tolerated under the guidance of expe-
rienced physicians [43]. As cysteamine toxicity may be asso-
ciated with copper deficiency in patients with renal Fanconi
syndrome, copper supplementation may prevent cysteamine-
related adverse effects in some patients [44].
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Long-term effects of cysteamine therapy
Long-term cysteamine treatment orally is associated with im-
provements in renal and extrarenal complications. A summary
of clinical data showing the long-term effects ofshown in
Table 1. Where reported [5, 45, 47], the duration of follow-
up ranged from 8 to 25 years, and the largest study comprised
data from 208 patients [49]. Of note, follow-up with early
treatment initiation is currently limited to <30 years; therefore,
the effects of cysteamine in older patients are unknown. It
should also be noted that, in some studies, the lack of adequate
cysteamine therapy may be due to insufficient access to treat-
ment (e.g., in developing countries), as well as poor treatment
compliance.
Renal outcomes
Although cysteamine does not significantly affect renal Fanconi
syndrome in most patients [1, 2], in patients with early initiation
and good treatment compliance, long-term cysteamine therapy
improves the evolution of renal function in patients with
cystinosis, delaying progression of glomerular function deterio-
ration, ESRD onset, and the need for renal transplantation [5, 16,
19, 45, 46, 50]. Early initiation was associated with preserved
renal function and reduced incidence of chronic kidney disease in
both aBrazilianmulticenter study [50] and a long-term retrospec-
tive study [5]. In the latter study, higher doses of cysteamine and
the use of angiotensin-converting enzyme inhibitors (ACEis)
were also significantly associated with a delay in the decline of
renal function [5]. Early initiation and adequate long-term cyste-
amine therapy delayed the onset of ESRD in the Necker-Enfants
Malades Hospital series of patients with cystinosis, who survived
to at least 20 years of age [46], and in a French study of adults
[45]. Increased compliance to cysteamine therapy also had a
linear correlation with the mean age at ESRD onset (R2 =
0.997) in a long-term retrospective study [19].
Taken together, these studies confirm that cysteamine ther-
apy orally must be initiated as early as possible following
diagnosis, even in small infants, and be used long term with
good compliance to maximize its beneficial effects on
delaying progression of renal failure and ESRD onset.
Extrarenal complications
In long-term studies, patients who initiated treatment early [5,
45, 46, 50, 51] and received adequate cysteamine therapy [16]
had increased life expectancy and fewer complications than
inadequately treated patients and those who started treatment
later or were untreated (Table 1). Given the strong evidence
for cysteamine-associated benefits and longer life expectancy
in most patients, there is increasing interest in improving pa-
tient care with regard to extrarenal disease manifestations,
treatment adherence, and adult patient care.
Eye disorders
Untreated patients with infantile nephropathic cystinosis de-
velop corneal cystine crystal accumulation that leads to ocular
discomfort and photophobia [1, 13]. As cysteamine therapy
orally has no effect on corneal cystine crystals, cysteamine eye
drops are used to dissolve crystals and reduce symptoms. A
new topical viscous formulation of cysteamine eye drops has
been developed that requires less frequent instillation and is
more effective than standard cysteamine eye drops [52].
Intracellular cystine crystal deposition can also occur in
posterior-segment ocular structures and is associated with
damage to retina, choroid, and optic nerve [13, 49]. Long-
term cysteamine therapy orally may reduce posterior-
segment complications. In a retrospective US National
Institutes of Health (NIH) study, a decreased incidence of
retinopathy from 28 to 0% was observed among patients with
cystinosis when therapy was increased from ≤10 years to 21–
30 years [49].
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Fig. 1 Cysteamine mechanism of
action. Reproduced from Cherqui
and Courtoy 2017 [23] (with
permission)
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Endocrine disorders
Long-term cysteamine therapy orally is associated with
marked improvements in growth retardation and other endo-
crine disorders [5, 16, 46, 47, 50]. Growth hormone therapy
may also improve growth outcomes [1]. Early initiation and
long-term therapy led to significantly improved mean height
[16, 46] and weight [16, 50] parameters in several studies.
Early initiation was also associated with improved linear
growth curves in an Italian study, where poorer linear growth
was observed in older children (in whom cysteamine was
started after 2.5 years of age and suboptimal treatment was
more likely) compared with those who initiated cysteamine
more recently [5]. Early therapy initiation is also associated
with a lower incidence of hypothyroidism and diabetes
mellitus [46, 50] and significant delays in the onset of these
conditions [45]. Furthermore, long-term (≥8 years) cyste-
amine therapy reduces the incidence of hypothyroidism and
diabetes in adults with cystinosis [16].
A long-term study (median follow-up 8 years) indicated
that good compliance to cysteamine therapy orally is effective
in preventing endocrine disorders in patients with cystinosis,
with ILC levels of <2 nmol half-cystine/mg protein being
associated with lower incidences of short stature, pubertal de-
lay, hypothyroidism, and diabetes than those with higher ILC
levels [47].
Neurocognitive disorders
Cystinosis is associated with several neurologic complica-
tions, including structural brain abnormalities, cognitive im-
pairment, and learning difficulties [8]. Long-term studies have
indicated that early initiation of cysteamine orallymay prevent
many of these neurocognitive disorders [46, 50, 51].
Cerebellar or pyramidal symptoms or mental deterioration
[46] or central nervous system disorders [50] were only ob-
served among patients who started cysteamine after 2 [50] or 3
[46] years of age. Early initiation (<2 years of age) is also
associated with significantly higher performance, verbal, and
full-scale IQ scores, and significantly improved visual–spatial
skills, although visual–motor skills were not significantly af-
fected [51].
Muscular disorders
Distal myopathy and muscle atrophy are significant compli-
cations of cystinosis among adolescents and young adults,
particularly in untreated patients and those with poor compli-
ance to cysteamine therapy [9]. The frequency and severity of
these complications can be reduced with long-term cyste-
amine, if initiated early. In adults, long-term (>20 years) ther-
apy was associated with a decrease in the incidence of myop-
athy (to 0%) compared with a treatment duration of ≤10 yearsTa
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(60%) [16], and the incidence of neuromuscular complica-
tions decreased significantly among patients who initiated
therapy early (<5 years) [45]. In two studies, oropharyngeal
dysfunction and/or distal muscle atrophy were only found in
patients who started therapy >2 [50] or 3 [46] years of age.
Swallowing dysfunction, which occurs due to muscle atrophy
and increases the risk of fatal aspiration, decreased in severity
with increased duration of treatment [48].
Pulmonary disorders
Patients with cystinosis may develop pulmonary complica-
tions, including respiratory failure caused by muscle weak-
ness, sleep apnea, and aspiration due to swallowing dysfunc-
tion [10]. In adults, longer-term cysteamine therapy is associ-
ated with a lower incidence of pulmonary disorders [16].
Mean forced vital capacity was higher among patients who
received cysteamine for >10 years (83% of predicted) than in
those with ≤10 years of therapy (54% of predicted) [16].
Mortality
Long-term cysteamine therapy is associated with improved
survival rates among patients with cystinosis, particularly
when initiated early [16, 45, 46]. In adults, long-term cyste-
amine was associated with lower mortality rates, with the in-
cidence of death decreasing as the duration of therapy in-
creased [16]; in other studies, lower rates of mortality were
observed among patients who started therapy early (<3 [46] or
5 [45] years).
Treatment adherence
The benefits of long-term cysteamine therapy are most evident
in patients with good compliance to treatment and are related
to the duration of therapy [18, 19]. In a retrospective NIH
study, each year of excellent cystine-depleting therapy result-
ed in almost 1 year of preserved renal function [19]. Treatment
tends to be most successful in children aged <11 years, as they
have the highest treatment adherence, largely due to adminis-
tration of cysteamine being conducted by a parent [18].
Conclusions
Inadequately treated cystinosis can lead to multisystem mor-
bidity and mortality. However, long-term cysteamine therapy,
if initiated early and used with good treatment compliance,
provides significant improvements in renal and extrarenal out-
comes. Early diagnosis and adequate long-term treatment are
therefore essential for preventing end-organ damage and
improving the overall prognosis in these patients. Major ef-
forts to maintain and promote adequate long-term cysteamine
therapy should be undertaken by healthcare professionals, pa-
tients, and supportive groups.
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